On May 6, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, reported that it had received "Notice of Allowance" from the Mexican Patent and Trademark Office (IMPI) in relation to the company’s patent titled: ‘System and method for high throughput screening of cancer cells’ (Press release, Cannabics Pharmaceuticals, MAY 6, 2021, View Source [SID1234579654]). The decision of the Mexican patent authority follows the European Patent Office (EPO) "Intention to Grant a European Patent" notice to the company from October 2020, concerning the same patent application.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eyal Barad, Cannabics Pharmaceuticals’ co-founder and CEO commented: "This patent application is a great example of Cannabics’s innovative and novel approach to the drug discovery process in our field. The patent was already granted in Israel and in South Africa, and we have been notified of intention to grant in Europe and now also in Mexico. This opens many interesting opportunities for the company in these markets, which we intend to develop and grow."